Pliant Therapeutics

Update in progress

PLRX (NasdaqGS)

Company RatingNeutral
SectorHealthcare
IndustryBiotechnology

Pliant Therapeutics, Inc. is a clinical-stage biopharmaceutical company developing integrin-based therapies for solid tumors. Its lead candidate, PLN-101095, is an oral, small-molecule dual inhibitor of αvβ8 and αvβ1 in Phase 1a/1b. The company also builds a drug discovery platform with a library of over 15,000 integrin-binding molecules aimed at integrin-based target-mediated delivery. Founded in 2015, based in South San Francisco.

Company score

Sentiment: -0.09; SentimentMeasures the overall tone of recent coverage and discussion about the company.−10 negative · 0 neutral · +10 positive
Environment: 0.00; EnvironmentAssesses the company’s environmental impact, risks, and sustainability practices.−10 negative · 0 neutral · +10 positive
Social: -0.21; SocialAssesses the company’s influence on employees, customers, communities, and wider society.−10 negative · 0 neutral · +10 positive
Governance: -0.10; GovernanceAssesses leadership, accountability, transparency, and business ethics.−10 negative · 0 neutral · +10 positive
Sustainability: -0.08; SustainabilityCombines environmental, social, and governance signals into an overall sustainability score.−10 negative · 0 neutral · +10 positive
Impact Score: -0.09; Impact ScoreCombines sentiment and sustainability performance into an assessment of the company’s overall impact.−10 negative · 0 neutral · +10 positive